Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2 Thoracic 1 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Neovascularization, Pathologic 1 Carcinoma, Renal Cell 1

Interventions

Docetaxel 409 pembrolizumab 331 Prednisone 290 enzalutamide 285 Gemcitabine 274 Radiotherapy 270 Magnetic Resonance Spectroscopy 269 Nivolumab 253 Abiraterone Acetate 218 Cisplatin 212 Leuprolide 195 Radiosurgery 192 Sunitinib 188 Carboplatin 161 Androgen Antagonists 156 bicalutamide 152 Specimen Handling 149 Goserelin 149 Ipilimumab 131 Paclitaxel 126 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122 apalutamide 118 Cyclophosphamide 117 Bevacizumab 116 Sorafenib 114 Everolimus 111 abiraterone 108 cabozantinib 105 atezolizumab 105 Biopsy 101

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rubidium-82 × Genitourinary × Clear all

NCT07346404 2026-01-16

RUBIKID

Assistance Publique - Hôpitaux de Paris

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Neovascularization, Pathologic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡